User:Mr. Ibrahem/Ponesimod
Clinical data | |
---|---|
Trade names | Ponvory |
Other names | ACT-128800 |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | 2 main metabolites |
Elimination half-life | 31–34 hrs[5] |
Excretion | Feces (57–80%, 26% unchanged), urine (10–18%)[6] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C23H25ClN2O4S |
Molar mass | 460.97 g·mol−1 |
3D model (JSmol) | |
| |
|
Ponesimod, sold under the brand name Ponvory, is a medication used to treat multiple sclerosis (MS).[3] Specifically it is used for the relapsing forms including clinically isolated syndrome, relapsing-remitting disease, and secondary progressive disease.[7][3] It is taken by mouth.[3]
Common side effects include upper respiratory tract infection, liver inflammation, and high blood pressure.[3] Other side effects may include infection, slow heart rate, breathing problems, and skin cancer.[3] Use during pregnancy may harm the baby.[3] It is a [[sphingosine 1-phosphate receptor modulator which decreases the activity of T and B cells.[3][7]
Ponesimod was approved for medical use in the United States and Europe in 2021.[3][7] In the United Kingdom 4 weeks of treatment costs the NHS about £1100 as of 2022.[8] In the United States this amount costs about 7,900 USD.[9]
References[edit]
- ^ a b "Ponvory APMDS". Therapeutic Goods Administration (TGA). 24 March 2022. Retrieved 4 April 2022.
{{cite web}}
: CS1 maint: url-status (link) - ^ "Summary Basis of Decision (SBD) for Ponvory". Health Canada. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
- ^ a b c d e f g h i j k l "Ponvory- ponesimod tablet, film coated Ponvory- ponesimod kit". DailyMed. Archived from the original on 21 January 2022. Retrieved 31 March 2021.
- ^ "Ponvory EPAR". European Medicines Agency (EMA). 24 March 2021. Archived from the original on 19 March 2022. Retrieved 18 December 2021.
- ^ Brossard P, Scherz M, Halabi A, Maatouk H, Krause A, Dingemanse J (February 2014). "Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration". Journal of Clinical Pharmacology. 54 (2): 179–88. doi:10.1002/jcph.244. PMID 24408162. S2CID 38041837.
- ^ Reyes M, Hoch M, Brossard P, Wagner-Redeker W, Miraval T, Dingemanse J (February 2015). "Mass balance, pharmacokinetics and metabolism of the selective S1P1 receptor modulator ponesimod in humans". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 45 (2): 139–49. doi:10.3109/00498254.2014.955832. PMID 25188442. S2CID 23905158.
- ^ a b c "European Medicines Agency Approval of Ponesimod". Archived from the original on 2021-08-04. Retrieved 2021-08-04.
- ^ "Ponesimod". SPS - Specialist Pharmacy Service. 12 January 2016. Archived from the original on 20 January 2022. Retrieved 31 October 2022.
- ^ "Ponvory". Archived from the original on 31 October 2022. Retrieved 31 October 2022.